Diabetes Mellitus, Type 2 Clinical Trial
— KIS-AntwerpOfficial title:
Prevention of Type 2 Diabetes and Gestational Diabetes Among Women of Reproductive Age in Kisantu, Democratic Republic of Congo
Verified date | January 2024 |
Source | Institute of Tropical Medicine, Belgium |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to develop and implement a long-term program focused on the prevention of type 2 diabetes Mellitus (T2DM) and gestational diabetes mellitus (GDM) in women of reproductive age through lifestyle modification. This is a cluster-randomized trial whereby 6 health centers across Kisantu, Democratic Republic of Congo (DRC) will be randomized to an intervention group (3 health centers) or a comparison group (3 health centers). The intervention group will be provided with a preventive program based on educational + motivational strategies when the comparison group will be limited to an educational strategy only. This study will last 24 months and is limited to women of reproductive age (18-49 years), pregnant and non-pregnant. Evaluation of this research will use mixed longitudinal analyses for healthy lifestyle adherence, anthropometric and clinical indicators, diet quality, and physical activity. Expected results of this study for women of reproductive age include the prevention of T2DM and GDM through the acquisition of healthy lifestyle behavior, reaching and maintaining an optimal weight, blood pressure and glycemia, and adhere to the weight gain recommendations during pregnancy. Other expected achievements encompass improvements in the usability of data capturing systems, expand knowledge among health care providers on effective strategies for T2DM and GDM prevention and improve the technique and precision of measurements concerning health visits among health care providers, among others.
Status | Active, not recruiting |
Enrollment | 288 |
Est. completion date | February 29, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - Non-pregnant or (first trimester) pregnant women - Women of reproductive age (18-49 years old) - Without a previous diagnosis of type 1 diabetes or T2DM (confirmed by a random glucose test) Exclusion Criteria: - Pregnant women with active gestational diabetes - Adult males, and children and adolescents <18 years old of both sexes - Pre-existent severe chronic conditions (e.g. chronic liver or kidney disease, chronic obstructive pulmonary disease) - Living outside of the surrounding catchment areas of the 6 healthcare centers. - Women internationally displaced, without a permanent home or identified physical address. - Women planning to move elsewhere in the following 2 years - Women that do not provide a written Informed Consent. |
Country | Name | City | State |
---|---|---|---|
Congo, The Democratic Republic of the | KAVWAYA | Kisantu | Kongo Central |
Congo, The Democratic Republic of the | KINKOKA | Kisantu | Kongo Central |
Congo, The Democratic Republic of the | Kintanu Etat | Kisantu | Kongo Cnetral |
Congo, The Democratic Republic of the | MADIMBA | Kisantu | Kongo Central |
Congo, The Democratic Republic of the | NGEBA | Kisantu | Kongo Central |
Congo, The Democratic Republic of the | NKANDU 1 | Kisantu | Kongo Central |
Lead Sponsor | Collaborator |
---|---|
Institute of Tropical Medicine, Belgium | Memisa, Belgium |
Congo, The Democratic Republic of the,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the adherence to a healthy lifestyle score at 24 months | The adherence to a healthy lifestyle will be measured by using a validated questionnaire for weight control in lifestyle-related diseases that compromise 14 questions, 12 regarding diet and 2 related to physical activity. Each question has 5 multiple choice answers (A, B, C, D, E). This questionnaire provides a final score ranging between 14-65 points. A lower score indicates poor adherence to a healthy lifestyle, while a high score indicates good adherence. | Baseline and 24 months | |
Primary | Change from baseline in the adherence to a healthy lifestyle score at 12 months | The adherence to a healthy lifestyle will be measured by using a validated questionnaire for weight control in lifestyle-related diseases that compromise 14 questions, 12 regarding diet and 2 related to physical activity. Each question has 5 multiple choice answers (A, B, C, D, E). This questionnaire provides a final score ranging between 14-65 points. A lower score indicates poor adherence to a healthy lifestyle, while a high score indicates good adherence. | Baseline and 12 months | |
Secondary | Change from baseline in the minimum diet diversity of women (MDD-W) questionnaire at 24 months | The MDD-W dichotomous questionnaire developed by the Food and Agriculture Organization of the United Nations (FAO) will be used to measure women's diet diversity. | Baseline and 24 months | |
Secondary | Change from baseline in the minimum diet diversity of women (MDD-W) questionnaire at 12 months | The MDD-W dichotomous questionnaire developed by the Food and Agriculture Organization of the United Nations (FAO) will be used to measure women's diet diversity. | Baseline and 12 months | |
Secondary | Change from baseline in the International Physical Activity Questionnaire at 24 months | The International Physical activity Questionnaire (IPAQ) short Form will be used to assess the level of physical activity of the participants. | Baseline and 24 months | |
Secondary | Change from baseline in the International Physical Activity Questionnaire at 12 months | The International Physical activity Questionnaire (IPAQ) short Form will be used to assess the level of physical activity of the participants. | Baseline and 12 months | |
Secondary | Change from baseline in weight at 24 months | Weight will be measured in kg and by using a digital weight scale. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 24 months | |
Secondary | Change from baseline in weight at 12 months | Weight will be measured in kg and by using a digital weight scale. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 12 months | |
Secondary | Change from baseline in Body mass index (BMI) at 24 months | BMI will be calculated by using the formula BMI= weight in kg/height in meters squared. | Baseline and 24 months | |
Secondary | Change from baseline in Body mass index (BMI) at 12 months | BMI will be calculated by using the formula BMI= weight in kg/height in meters squared. | Baseline and 12 months | |
Secondary | Change from baseline in waist circumference at 24 months | Waist circumference will be measured in cm and y using a constant tension tape. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 24 months | |
Secondary | Change from baseline in waist circumference at 12 months | Waist circumference will be measured in cm and y using a constant tension tape. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 12 months | |
Secondary | Change from baseline in glycemia at 24 months | Glycemia will be measured in mg/dL by using by pricking the fingertip with a lancet and glucometer. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 24 months | |
Secondary | Change from baseline in glycemia at 12 months | Glycemia will be measured in mg/dL by using by pricking the fingertip with a lancet and glucometer. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 12 months | |
Secondary | Change from baseline in systolic and diastolic blood pressure at 24 months | Systolic and diastolic blood pressure will me measured in mm Hg and by using an OMRON. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 24 months | |
Secondary | Change from baseline in systolic and diastolic blood pressure at 12 months | Systolic and diastolic blood pressure will me measured in mm Hg and by using an OMRON. The WHO STEPwise guideline will be followed for this measurement. | Baseline and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |